

DESH RAKSHAK AUSHDHALAYA LIMITED

BHAGWANT KUTI KANKHAL-249408, HARIDWAR (UTTARAKHAND) INDIA

Manufacturers of Ayurvedic and Herbal Product

Phone: (01334) 243833, 245877, 242333 Tele Fax: (01334) 245866

E-mail: dral95@yahoo.com, dral96@yahoo.in website: www.deshrakshak.in

To,
Corporate Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Date: 13.08.2026

BSE Scrip Code: 531521

Sub: Outcome of Board Meeting held on Thursday, 13th day of August, 2026 Meeting Commenced at 12:30 P.M. and concluded at 01:55 P.M pursuant to Para A of Part A of Schedule III and Regulation 30 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th day of July, 2023.

Respected Sir/Mam,

With reference to the captioned subject, the company Desh Rakshak Aushdhalaya Limited ("the Company") (CIN: L33119UR1981PLC006092), hereby inform that the Board of Directors of the Company in its meeting held on Thursday, 13th day of August, 2026 at the registered office of the Company Bhagwant Kuti Kankhal, Haridwar, Uttarakhand- 249408 India has discussed, considered and took noted and approved the following matters:

1. All the directors of the Company duly presented in the meeting and hence there was no leave of absence granted.
2. Took noted the minutes of the previous meeting of Board of Directors of the Company.
3. Considered and took noted of the tripartite agreement entered by the Company with M/s. MAS Services Limited (OLD RTA) and M/s. Nivis Corpserve LLP (NEW RTA) on June 20, 2026 with respect to RTA services.
4. Considered and Approved the quarterly and year to date Un-Audited Financial Results for the first quarter ended on 30th day of June, 2026.
5. Considered and Approved the Limited Review Report on the quarterly and year to date Financial Results for the first quarter ended on 30th day of June, 2026.

DESH RAKSHAK AUSHDHALAYA LIMITED

BHAGWANT KUTI KANKHAL-249408, HARIDWAR (UTTARAKHAND) INDIA

Manufacturers of Ayurvedic and Herbal Product

Phone: (01334) 243833, 245877, 242333 Tele Fax: (01334) 245866

E-mail: dral95@yahoo.com, dral96@yahoo.in website: www.deshrakshak.in

Pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company enclose herewith:

- (i) Limited Review Report dated 13th August, 2026 with unmodified opinion of Anil Jain and Co., Chartered Accountants, Statutory Auditors, in respect of the Quarterly and Year to date Financial Results for the quarter ended 30th June, 2026.
- (ii) Unaudited Financial Results for the quarter and year to date ended 30th June, 2026, which were approved by the Board of Directors and signed by the Managing Director.
- (iii) Declaration by the Company in respect of unmodified opinion.

Kindly take this information on your records.

Thanking you,
Yours faithfully,

For Desh Rakshak Aushdhalaya Limited

Tosh Kumar Jain
Managing Director
DIN: 01540363

Date: August 13, 2026

Place: Haridwar

Independent Auditor's Limited Review Report on Standalone Unaudited Quarterly/Half Yearly/Year to date Financial Results of the Desh Rakshak Aushdhalaya Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

Review report to
The Board of Directors,
Desh Rakshak Aushdhalaya Limited
Bhagwant Kuti Kankhal, Haridwar, Uttarakhand-249408 India


We have reviewed the accompanying statement of Unaudited financial results ("the Statement") of Desh Rakshak Aushdhalaya Limited for the Quarter and three Months ended June 30, 2026, being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matter.

FOR AND ON BEHALF OF
M/S ANIL JAIN & CO.
CHARTERED ACCOUNTANTS



PLACE: HARIDWAR
DATED: 13.08.2026


[ANIL KUMAR JAIN]
PROPRIETOR
MEMBERSHIP NO.070253
UDIN: 26070253NPGCTH8477

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR TO DATE ENDED 30TH JUNE, 2026

Particulars	(Rupees in Lakhs Except Earning Per Equity Share and Face Value Per Equity Share)				
	Quarter Ended (3 Months Ended)			Year Ended	
	30-Jun-2026 Un Audited	31-Mar-2026 Audited	30-Jun-2025 UnAudited	31-Mar-2026 Audited	31-Mar-2025 Audited
(Refer Notes Below)					
I. Revenue from operations	82.83	345.33	129.99	710.44	627.06
II. Other Income	0.00	1.05	0.00	1.05	3.32
III. Total Revenue (I)+(II)	82.83	346.38	129.99	711.49	630.38
IV. Expenses					
Cost of Materials consumed	8.22	180.91	50.33	298.33	256.77
Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of raw material, work-in-progress and finished goods-in-trade	0.00	0.00	0.00	0.00	0.00
Employees benefits expense	22.89	26.81	26.04	103.12	96.62
Finance Cost	5.40	9.61	5.41	28.40	29.81
Depreciation and amortisation expense	10.91	12.80	10.04	43.64	41.60
Other expenses	27.38	75.45	28.58	170.48	149.11
Total Expenses	74.80	305.58	120.40	643.97	573.91
V. Profit/(Loss) before exceptional and extraordinary items and tax (III- IV)	8.03	40.80	9.59	67.52	56.47
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before extraordinary items and tax (V-VI)	8.03	40.80	9.59	67.52	56.47
VIII. Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX. Profit and Losses before taxes (VII- VIII)	8.03	40.80	9.59	67.52	56.47
X. Tax Expense					
(1) Current tax	0.00	11.30	0.00	11.30	8.81
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
XI. Net Profit/(Loss) for the period from continuing operations (IX- X)	8.03	29.50	9.59	56.22	47.66
XII. Profit/(Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII. Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV. Profit/(Loss) for the period (XI+XIV)	8.03	29.50	9.59	56.22	47.66
XVI. Other Comprehensive Income / (Expense) (OCI)					
A. (i) Items that will not be reclassified to Profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
B. (i) Items that will be reclassified to Profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
Total Other Comprehensive Income / (Expense) (OCI) (A+ B)	0.00	0.00	0.00	0.00	0.00
Total Comprehensive Income/ (Expense) for the period (XV+XVI)	8.03	29.50	9.59	56.22	47.66
XVII. Paid-up equity share capital (Face Value of the share shall be indicated)	569.83	569.83	443.83	569.83	443.83
Face Value Per Equity Share	10.00	10.00	10.00	10.00	10.00
XVIII. Reserve excluding revaluation reserves as per balance sheet of previous accounting year				523.61	475.94
XIX. Earning Per Equity Share					
(a) Basic	0.14	0.52	0.22	0.99	1.07
(b) Diluted	0.14	0.52	0.22	0.99	1.07

Notes

- (1) The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their Meeting held on 13th day of August, 2026.
- (2) The above results have been reviewed by the Statutory Auditors of the Company.
- (3) Previous quarter/year figures have been restated wherever necessary to make them comparable.
- (4) Disclosure of segment wise information as per AS-17 is not applicable, as dealing with Ayurvedic Medicines is the company's only business Segments
- (5) In terms of Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, there were no investor complaint pending at the beginning of the quarter or lying unresolved at 30-06-2026.
- (6) The members of the Company in the Extra-Ordinary General Meeting held on May 29, 2025 approved issuance of 12,60,000 equity shares through preferential allotment having face value of Rs. 10 each at the issue price of Rs. 22 each, in terms of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other securities laws. The Company received in-principal approval approval from the BSE Limited on August 26, 2025 for the preferential issue. The Board of directors in the meeting held on September 09, 2025 approved allotment by way of preferential issue of 12,60,000 equity shares of face value of Rs. 10/- each of the Company for cash at a price of Rs. 22/- per equity share. The Company received listing approval for the above mentioned equity shares issued on preferential basis on October 10, 2025. The Company also received trading approval for the above mentioned equity shares issued on preferential basis with effect from October 27, 2025. The Company raised amount of Rs. 2,77,20,000 through allotment of above mentioned equity shares through preferential issue on September 09, 2025.
- (7) The Company does not have any subsidiary/associate/joint venture entity(ies) for the quarter and year to date ended 30th June, 2026.
- (8) The Figures of last quarter ended on 31-03-2026 are the balancing figures between audited figures in respect of the full financial year ended 31-03-2026 and the published year-to-date figures for the third quarter ended 31-12-2025 of the respective financial year.

For DESH RAKSHAK AUSHDHALAYA LIMITED

Date: 13.08.2026
Place: Haridwar

TOSH KUMAR JAIN
Managing Director
[DIN-01540363]

DESH RAKSHAK AUSHDHALAYA LIMITED

BHAGWANT KUTI KANKHAL-249408, HARIDWAR (UTTARAKHAND) INDIA

Manufacturers of Ayurvedic and Herbal Product

Phone: (01334) 243833, 245877, 242333 Tele Fax: (01334) 245866

E-mail: dral95@yahoo.com, dral96@yahoo.in website: www.deshrakshak.in

To,
Corporate Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Date: 13.08.2026

Respected Sir/Mam,

BSE Scrip Code: 531521

Declaration pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with Securities and Exchange Board of India circular No. CIR/CFD/CMD/56/2016 dated 27.05.2016

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Securities and Exchange Board of India Circular No. CIR/CFD/CMD/56/2016 dated 27.05.2016, the company Desh Rakshak Aushdhalaya Limited ("**the Company**") (CIN: L33119UR1981PLC006092) hereby confirm and declare that the Statutory Auditors of the Company, Anil Jain and Co., Chartered Accountants, have issued an Limited Review Report on the Standalone Quarterly and year to date Unaudited Financial Results for the quarter ended 30th June, 2026 with unmodified opinion.

Request you to please take the above on record.

Thanking You,
Yours Faithfully
For Desh RakshakAushdhalaya Limited

Tosh Kumar Jain
(Managing Director)
DIN: 01540363

Date: 13.08.2026
Place: Haridwar